HAE is a rare genetic disease characterized by recurrent attacks of localized oedema (swelling). European regulators have approved a label extension for Shire’s Firazyr, broadening its use include adolescents and children aged two years and older with a particular type of HAE.Firazyr (icatibant) was approved in 2008 for adults with C1-esterase-inhibitor (C1-INH) deficiency, expanding its reach to children offers a new treatment option for relief of symptoms. HAE is a rare genetic disease characterised by recurrent attacks of localised oedema, most commonly affecting the extremities, gastrointestinal tract and, less frequently, upper airways. “As a long-term partner to the HAE community, we understand the unique burden this disease places on children living with HAE and their caregivers,” said Jennifer Schranz, Global Development lead, HAE, Shire. “This approval in Europe demonstrates our unwavering commitment to helping patients and represents a significant advance for paediatric patients, who now have a subcutaneous treatment option for acute HAE attacks.” Approval was based on an open label, non-randomised, single-arm study, with a primary efficacy endpoint of time to onset of symptom relief (TOSR). Overall, median TOSR was 1.0 hour, with no differences between children and adolescents. More than 70 percent of patients experienced symptom relief at 1.1 hours, and more than 90 percent by 2 hours post-treatment. The study showed Firazyr was well tolerated and demonstrated rapid resolution of symptoms during an HAE attack through a single injection, Shire noted. This is from Pharma Times.
Blog
Many notable peptide experts and companies were invited to attend the peptide seminar.
PCHi (The Personal Care and Homecare Ingredients) is rotated annually between Changjiang Delta and Zhuhai Delta - two of China’s most affluent business areas that are also key manufacturing hubs for the personal care, cosmetics, toiletries and home care industry. It draws business professionals such as formulators, manufacturers, R&D technologists, and senior management from all corners of the global community.
ZPC will show up at the event and provide best-in-class cosmetic peptides to the customers from all over the world. Peptide is composed of amino acids which has no side-effect and very permeable to the deeper skin. It's a very ideal ingredient for the pharmaceutical and cosmetic products. There are the cosmetic functions of anti-aging, anti-wrinkle, eyebags removal, hair growth, skin repair and breast enhancement, etc.
Venue: Shanghai World EXPO Exhibition & Convention Center (SWEECC)
Date: 19 – 21 March 2018 (Monday to Wednesday)
Opening times: 9am to 5pm (Monday to Tuesday) 9 am to 4 pm (Wednesday)
ZPC attended PCHi Shanghai.
We had the meeting with clients from all over the world. Peptides are favored by many cosmetics companies.
Thanks so much for everyone support.